Canna~Fangled Abstracts

An Exploratory Human Laboratory Experiment Evaluating Vaporized Cannabis in the Treatment of Neuropathic Pain from Spinal Cord Injury and Disease.

By June 7, 2016May 24th, 2020No Comments
2016 Jun 7. pii: S1526-5900(16)30072-4. doi: 10.1016/j.jpain.2016.05.010. [Epub ahead of print]

Author information


  • Vaporized cannabis positively affected all of the neuropathic pain descriptors
  • There was significantly more pain relief with active cannabis compared to placebo
  • The two active doses did not significantly differ from each other in terms of analgesic potency
  • Many of the psychoactive side effects were delta 9-THC concentration-dependent

Abstract

Using eight hour human laboratory experiments, we evaluated the analgesic efficacy of vaporized cannabis in patients with neuropathic pain related to injury or disease of the spinal cord, the majority of whom were experiencing pain despite traditional treatment. After obtaining baseline data, 42 participants underwent a standardized procedure for inhaling 4 puffs of vaporized cannabis containing either placebo, 2.9%, or 6.7% delta-9-tetrahydrocannabinol on three separate occasions. A second dosing occurred 3 hours later; participants chose to inhale 4 to 8 puffs. This flexible dosing was utilized to attempt to reduce the placebo effect. Using an 11-point numerical pain intensity rating scale as the primary outcome, a mixed effects linear regression model demonstrated a significant analgesic response for vaporized cannabis. When subjective and psychoactive side effects (e.g., good drug effect, feeling high, etc.) were added as covariates to the model, the reduction in pain intensity remained significant above and beyond any effect of these measures (all p<0.0004). Psychoactive and subjective effects were dose dependent. Measurement of neuropsychological performance proved challenging because of various disabilities in the population studied. As the two active doses did not significantly differ from each other in terms of analgesic potency, the lower dose appears to offer the best risk-benefit ratio in patients with neuropathic pain associated with injury or disease of the spinal cord.

PERSPECTIVE:

A cross-over, randomized, placebo-controlled human laboratory experiment involving administration of vaporized cannabis was performed in patients with neuropathic pain related to spinal cord injury and disease. This study supports consideration of future research that would include longer duration studies over weeks to months in order to evaluate the efficacy of medicinal cannabis in patients with central neuropathic pain.
Copyright © 2016 American Pain Society. Published by Elsevier Inc. All rights reserved.

KEYWORDS:

analgesia; cannabis; clinical trial; neuropathic pain; neuropsychological testing

PMID: 27286745
[PubMed – as supplied by publisher]
twin memes II
en English
X